News stories about Eiger Biopharmaceuticals (NASDAQ:EIGR) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Eiger Biopharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.810569382563 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) traded up $0.50 during midday trading on Monday, hitting $8.65. 86,116 shares of the stock were exchanged, compared to its average volume of 257,538. The firm has a market capitalization of $88.34, a PE ratio of -1.63 and a beta of 1.91. The company has a debt-to-equity ratio of 1.19, a current ratio of 5.78 and a quick ratio of 5.78. Eiger Biopharmaceuticals has a 1-year low of $6.10 and a 1-year high of $16.20.
A number of equities analysts have weighed in on the stock. ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 14th. Wedbush restated a “buy” rating on shares of Eiger Biopharmaceuticals in a research report on Wednesday, October 25th. Zacks Investment Research cut shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Oppenheimer set a $34.00 price objective on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research report on Monday, October 23rd. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $17.00 target price (down from $35.00) on shares of Eiger Biopharmaceuticals in a research report on Tuesday, January 16th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Eiger Biopharmaceuticals has an average rating of “Buy” and a consensus target price of $27.25.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/12/eiger-biopharmaceuticals-eigr-earns-daily-news-sentiment-rating-of-0-17.html.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.